tetano
Editor, Senior Moderator
Diagn Microbiol Infect Dis
. 2020 Aug 29;99(1):115197.
doi: 10.1016/j.diagmicrobio.2020.115197. Online ahead of print.
Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19
Heini Flinck[SUP] 1 [/SUP], Anne Rauhio[SUP] 2 [/SUP], Bruno Luukinen[SUP] 3 [/SUP], Terho Lehtim?ki[SUP] 4 [/SUP], Anna-Maija Haapala[SUP] 3 [/SUP], Tapio Seiskari[SUP] 3 [/SUP], Janne Aittoniemi[SUP] 3 [/SUP]
Affiliations
Abstract
Automated assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) diagnostics have recently come available. We compared the performance of the Elecsys? Anti-SARS-CoV-2 and LIAISON? SARS-CoV-2 S1/S2 IgG tests. The seroconversion panel comprised of 120 samples from 13 hospitalized COVID-19 patients. For the sensitivity and specificity testing, samples from COVID-19 outpatients >15 days after positive nucleic acid amplification test (NAAT) result (n = 35) and serum control samples collected before the COVID-19 era (n = 161) were included in the material. Samples for the detection of possible cross-reactions were also tested. Based on our results, the SARS-CoV-2 antibodies can be quite reliably detected 2 weeks after NAAT positivity and 3 weeks after the symptom onset with both tests. However, since some COVID-19 patients were positive only with Elecsys?, the antibodies should be screened against N-antigen (Elecsys?) and reactive samples confirmed with S antigen (LIAISON?), but both results should be reported. In some COVID-19 patients, the serology can remain negative.
Keywords: Antibody; COVID-19; Elecsys; LIAISON; SARS-CoV-2; Serology.
. 2020 Aug 29;99(1):115197.
doi: 10.1016/j.diagmicrobio.2020.115197. Online ahead of print.
Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19
Heini Flinck[SUP] 1 [/SUP], Anne Rauhio[SUP] 2 [/SUP], Bruno Luukinen[SUP] 3 [/SUP], Terho Lehtim?ki[SUP] 4 [/SUP], Anna-Maija Haapala[SUP] 3 [/SUP], Tapio Seiskari[SUP] 3 [/SUP], Janne Aittoniemi[SUP] 3 [/SUP]
Affiliations
- PMID: 32977117
- DOI: 10.1016/j.diagmicrobio.2020.115197
Abstract
Automated assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) diagnostics have recently come available. We compared the performance of the Elecsys? Anti-SARS-CoV-2 and LIAISON? SARS-CoV-2 S1/S2 IgG tests. The seroconversion panel comprised of 120 samples from 13 hospitalized COVID-19 patients. For the sensitivity and specificity testing, samples from COVID-19 outpatients >15 days after positive nucleic acid amplification test (NAAT) result (n = 35) and serum control samples collected before the COVID-19 era (n = 161) were included in the material. Samples for the detection of possible cross-reactions were also tested. Based on our results, the SARS-CoV-2 antibodies can be quite reliably detected 2 weeks after NAAT positivity and 3 weeks after the symptom onset with both tests. However, since some COVID-19 patients were positive only with Elecsys?, the antibodies should be screened against N-antigen (Elecsys?) and reactive samples confirmed with S antigen (LIAISON?), but both results should be reported. In some COVID-19 patients, the serology can remain negative.
Keywords: Antibody; COVID-19; Elecsys; LIAISON; SARS-CoV-2; Serology.